Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)
再燃性多発性硬化症の参加者を対象に、レミブルチニブとテリフルノミドの有効性と安全性を比較した無作為化二重盲検二重ダミー並行群間試験、その後非盲検レミブルチニブによる長期治療
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)
調査の概要
詳細な説明
The study CLOU064C12302 consists of an initial Core Part (CP) (maximum duration per participant of up to 30 months), followed by an Extension Part (EP, of up to 5 years duration) for eligible participants.
The Core Part is a randomized, double-blind, double-dummy, active comparator-controlled, fixed-dose, parallel-group, multi-center study in approximately 800 participants with relapsing multiple sclerosis (RMS).
The Extension Part is an open-label, single-arm, fixed-dose design in which eligible participants are treated with remibrutinib for up to 5 years.
A second study of identical design (CLOU064C12301) will be conducted simultaneously. Both studies will be conducted globally and data from the two studies will be pooled for some of the endpoints.
研究の種類
入学 (実際)
段階
- フェーズ 3
連絡先と場所
研究場所
-
-
Arizona
-
Phoenix、Arizona、アメリカ、85018
- Ctr for Neurology and Spine
-
-
California
-
Hanford、California、アメリカ、93230
- Vladimir Royter MD APMC
-
Los Angeles、California、アメリカ、90073
- VA Greater LA Healthcare System
-
West Hollywood、California、アメリカ、90048
- Regina Berkovich MD PhD Inc
-
-
Colorado
-
Aurora、Colorado、アメリカ、80045
- CU Anschutz Med Campus
-
Denver、Colorado、アメリカ、80210
- Colorado Neurological Research PC
-
-
Connecticut
-
Stamford、Connecticut、アメリカ、06905
- New England Institute for Clinical Research
-
-
District of Columbia
-
Washington D.C.、District of Columbia、アメリカ、20007
- Georgetown University Hospital
-
Washington D.C.、District of Columbia、アメリカ、20007
- Georgetown University Hospital Research
-
-
Florida
-
Bradenton、Florida、アメリカ、34209
- Nova Clinical Research LLC
-
Gainesville、Florida、アメリカ、32610
- University of Florida
-
Hollywood、Florida、アメリカ、33021
- Memorial Healthcare System
-
Maitland、Florida、アメリカ、32751
- Neurology Associates PA
-
Miami、Florida、アメリカ、33136
- UM Department Of Neurology
-
Miami、Florida、アメリカ、33133
- Gables Neurology
-
Naples、Florida、アメリカ、34105
- Aqualane Clinical Research
-
Orlando、Florida、アメリカ、32803
- Advent Health Orlando
-
Pembroke Pines、Florida、アメリカ、33024
- Humanity Clinical Research
-
Pensacola、Florida、アメリカ、32514
- Emerald Coast Neurology
-
Port Orange、Florida、アメリカ、32127
- Brain and Spine Institute
-
Vero Beach、Florida、アメリカ、32960
- Vero Beach Neurology
-
Winter Park、Florida、アメリカ、32789
- Conquest Research
-
-
Indiana
-
Merrillville、Indiana、アメリカ、46410
- Methodist Neuroscience Institute
-
-
Kansas
-
Kansas City、Kansas、アメリカ、66160
- University of Kansas Hospital
-
-
Kentucky
-
Nicholasville、Kentucky、アメリカ、40356
- Baptist Physicians Lexington
-
-
Louisiana
-
New Orleans、Louisiana、アメリカ、70121
- Ochsner Clinic Foundation
-
-
Maryland
-
Frederick、Maryland、アメリカ、21702
- Clinre Comprehensive Neurology
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02111
- Tufts Medical Center
-
-
Missouri
-
Kansas City、Missouri、アメリカ、64128
- Kansas City VA Medical Center
-
-
New York
-
Patchogue、New York、アメリカ、11772
- South Shore Neurologic Associates
-
-
North Carolina
-
Chapel Hill、North Carolina、アメリカ、27599-9500
- University Of NC At Chapel Hill
-
Charlotte、North Carolina、アメリカ、28210
- Piedmont HealthCare
-
-
Ohio
-
Columbus、Ohio、アメリカ、43235
- The Boster Ctr for MS
-
Dayton、Ohio、アメリカ、45408
- Neurology Diagnostics Inc
-
-
Pennsylvania
-
Hershey、Pennsylvania、アメリカ、17033
- Penn State Hershey Medical Center
-
-
South Carolina
-
Greenville、South Carolina、アメリカ、29605
- Premier Neurology
-
Old Point Station、South Carolina、アメリカ、29707
- Metrolina Neurological Associates PA
-
-
Tennessee
-
Knoxville、Tennessee、アメリカ、37922
- Sibyl Wray MD Neurology PC
-
-
Texas
-
Dallas、Texas、アメリカ、75231
- Carum Research
-
El Paso、Texas、アメリカ、79935
- Med Research Inc
-
Frisco、Texas、アメリカ、75035
- Lone Star Neurology
-
San Antonio、Texas、アメリカ、78258
- Lonestar Neurology of San Antonio
-
San Antonio、Texas、アメリカ、78229
- UT Health MARC Medical Arts and Research Center
-
Sherman、Texas、アメリカ、75092
- Texas Institute for Neurological Disorders
-
Temple、Texas、アメリカ、76508
- Baylor Scott and White
-
-
Washington
-
Seattle、Washington、アメリカ、98101
- Virginia Mason Medical Centre
-
Seattle、Washington、アメリカ、98133
- University of Washington MS Clinic
-
-
West Virginia
-
Crab Orchard、West Virginia、アメリカ、25827
- Elligo Health Research
-
-
Wisconsin
-
Milwaukee、Wisconsin、アメリカ、53226
- Medical College of Wisconsin
-
Milwaukee、Wisconsin、アメリカ、53215
- Ascension St Francis Center
-
-
-
-
-
Buenos Aires、アルゼンチン、C1012AAR
- Novartis Investigative Site
-
CABA、アルゼンチン、C1181ACH
- Novartis Investigative Site
-
Córdoba、アルゼンチン、X5004CDT
- Novartis Investigative Site
-
-
Mendoza Province
-
Bombal、Mendoza Province、アルゼンチン、M5500DXO
- Novartis Investigative Site
-
-
Santa Fe Province
-
Rosario、Santa Fe Province、アルゼンチン、S2000BZL
- Novartis Investigative Site
-
Rosario、Santa Fe Province、アルゼンチン、S2000DSW
- Novartis Investigative Site
-
-
Tucumán Province
-
San Miguel de、Tucumán Province、アルゼンチン、T4000
- Novartis Investigative Site
-
-
-
-
Invernesshire
-
Inverness、Invernesshire、イギリス、IV2 3RE
- Novartis Investigative Site
-
-
Kent
-
Canterbury、Kent、イギリス、CT1 3NG
- Novartis Investigative Site
-
-
-
-
-
Naples、イタリア、80138
- Novartis Investigative Site
-
-
BR
-
Brindisi、BR、イタリア、72100
- Novartis Investigative Site
-
-
FG
-
Foggia、FG、イタリア、71122
- Novartis Investigative Site
-
-
IS
-
Pozzilli、IS、イタリア、86077
- Novartis Investigative Site
-
-
ME
-
Messina、ME、イタリア、98124
- Novartis Investigative Site
-
-
MO
-
Modena、MO、イタリア、41126
- Novartis Investigative Site
-
-
PV
-
Pavia、PV、イタリア、27100
- Novartis Investigative Site
-
-
TO
-
Orbassano、TO、イタリア、10043
- Novartis Investigative Site
-
-
-
-
Kerala
-
Kochi、Kerala、インド、682025
- Novartis Investigative Site
-
-
Maharashtra
-
Pune、Maharashtra、インド、411013
- Novartis Investigative Site
-
-
National Capital Territory of Delhi
-
New Delhi、National Capital Territory of Delhi、インド、110060
- Novartis Investigative Site
-
-
Punjab
-
Amritsar、Punjab、インド、143006
- Novartis Investigative Site
-
-
Telangana
-
Hyderabad、Telangana、インド、500082
- Novartis Investigative Site
-
-
Uttar Pradesh
-
Lucknow、Uttar Pradesh、インド、226007
- Novartis Investigative Site
-
-
West Bengal
-
Kolkata、West Bengal、インド、700017
- Novartis Investigative Site
-
-
-
-
-
Tallinn、エストニア、11315
- Novartis Investigative Site
-
Tartu、エストニア、50406
- Novartis Investigative Site
-
-
-
-
Alberta
-
Edmonton、Alberta、カナダ、T6G 2B7
- Novartis Investigative Site
-
-
British Columbia
-
Burnaby、British Columbia、カナダ、V5G 2X6
- Novartis Investigative Site
-
-
Nova Scotia
-
Halifax、Nova Scotia、カナダ、B3H 4K4
- Novartis Investigative Site
-
-
Ontario
-
Ottawa、Ontario、カナダ、K1H 8L6
- Novartis Investigative Site
-
-
Quebec
-
Lévis、Quebec、カナダ、G6W 0M5
- Novartis Investigative Site
-
Montreal、Quebec、カナダ、H4A 3T2
- Novartis Investigative Site
-
Québec、Quebec、カナダ、G1J 1Z4
- Novartis Investigative Site
-
Saint-Jérôme、Quebec、カナダ、J7Z 5T3
- Novartis Investigative Site
-
-
-
-
-
Athens、ギリシャ、115 28
- Novartis Investigative Site
-
Athens、ギリシャ、115 26
- Novartis Investigative Site
-
Chaïdári、ギリシャ、124 62
- Novartis Investigative Site
-
Ioannina、ギリシャ、455 00
- Novartis Investigative Site
-
Larissa、ギリシャ、411 10
- Novartis Investigative Site
-
Thessaloniki、ギリシャ、532 46
- Novartis Investigative Site
-
Thessaloniki、ギリシャ、546 36
- Novartis Investigative Site
-
-
-
-
-
Zagreb、クロアチア、10000
- Novartis Investigative Site
-
-
Croatia
-
Zagreb、Croatia、クロアチア、10000
- Novartis Investigative Site
-
-
HRV
-
Split、HRV、クロアチア、21000
- Novartis Investigative Site
-
Varaždin、HRV、クロアチア、42000
- Novartis Investigative Site
-
-
Vukovar
-
Vukovar、Vukovar、クロアチア、32000
- Novartis Investigative Site
-
-
-
-
-
Stockholm、スウェーデン、102 35
- Novartis Investigative Site
-
-
-
-
-
Lleida、スペイン、25198
- Novartis Investigative Site
-
Madrid、スペイン、28040
- Novartis Investigative Site
-
Madrid、スペイン、28009
- Novartis Investigative Site
-
Málaga、スペイン、29016
- Novartis Investigative Site
-
Seville、スペイン、41009
- Novartis Investigative Site
-
Valencia、スペイン、46026
- Novartis Investigative Site
-
-
A Coruna
-
Santiago Compostela、A Coruna、スペイン、15706
- Novartis Investigative Site
-
-
Araba
-
Vitoria-Gasteiz、Araba、スペイン、01009
- Novartis Investigative Site
-
-
Barcelona
-
L'Hospitalet de Llobregat、Barcelona、スペイン、08907
- Novartis Investigative Site
-
-
Castille-La Mancha
-
Albacete、Castille-La Mancha、スペイン、02006
- Novartis Investigative Site
-
-
Catalonia
-
Barcelona、Catalonia、スペイン、08003
- Novartis Investigative Site
-
-
La Rioja
-
Logroño、La Rioja、スペイン、26006
- Novartis Investigative Site
-
-
Madrid
-
Pozuelo de Alarcón、Madrid、スペイン、28223
- Novartis Investigative Site
-
Torrejón de Ardoz、Madrid、スペイン、28850
- Novartis Investigative Site
-
-
Principality of Asturias
-
Gijón、Principality of Asturias、スペイン、33394
- Novartis Investigative Site
-
-
Valencia
-
Valencia、Valencia、スペイン、46017
- Novartis Investigative Site
-
-
-
-
-
Banská Bystrica、スロバキア、975 17
- Novartis Investigative Site
-
Banská Bystrica、スロバキア、974 04
- Novartis Investigative Site
-
Bratislava、スロバキア、833 05
- Novartis Investigative Site
-
-
-
-
-
Celje、スロベニア、3000
- Novartis Investigative Site
-
Ljubljana、スロベニア、1000
- Novartis Investigative Site
-
-
Slovenia
-
Maribor、Slovenia、スロベニア、2000
- Novartis Investigative Site
-
-
-
-
-
Brno、チェコ、602 00
- Novartis Investigative Site
-
Hradec Králové、チェコ、500 05
- Novartis Investigative Site
-
Teplice、チェコ、415 29
- Novartis Investigative Site
-
-
-
-
-
Konya、トルコ(Türkiye)、42130
- Novartis Investigative Site
-
-
Atakum
-
Samsun、Atakum、トルコ(Türkiye)、55200
- Novartis Investigative Site
-
-
Balcova
-
Izmir、Balcova、トルコ(Türkiye)、35340
- Novartis Investigative Site
-
-
Fatih
-
Istanbul、Fatih、トルコ(Türkiye)、34098
- Novartis Investigative Site
-
Istanbul、Fatih、トルコ(Türkiye)、34093
- Novartis Investigative Site
-
-
Karabaglar
-
Izmir、Karabaglar、トルコ(Türkiye)、35150
- Novartis Investigative Site
-
-
Kocaeli
-
Köseköy、Kocaeli、トルコ(Türkiye)、41380
- Novartis Investigative Site
-
-
Melikgazi
-
Kayseri、Melikgazi、トルコ(Türkiye)、38039
- Novartis Investigative Site
-
-
Nilufer
-
Bursa、Nilufer、トルコ(Türkiye)、16140
- Novartis Investigative Site
-
-
Pendik
-
Istanbul、Pendik、トルコ(Türkiye)、34899
- Novartis Investigative Site
-
-
Sancaktepe
-
Istanbul、Sancaktepe、トルコ(Türkiye)、34785
- Novartis Investigative Site
-
-
-
-
-
Essen、ドイツ、45147
- Novartis Investigative Site
-
Hamburg、ドイツ、22179
- Novartis Investigative Site
-
-
Baden-Wurttemberg
-
Freiburg im Breisgau、Baden-Wurttemberg、ドイツ、79106
- Novartis Investigative Site
-
-
-
-
-
Caen、フランス、14033
- Novartis Investigative Site
-
Clermont-Ferrand、フランス、63003
- Novartis Investigative Site
-
Dijon、フランス、21000
- Novartis Investigative Site
-
Gonesse、フランス、95500
- Novartis Investigative Site
-
Grenoble、フランス、38043
- Novartis Investigative Site
-
Lille、フランス、59037
- Novartis Investigative Site
-
Lille、フランス、59000
- Novartis Investigative Site
-
Nice、フランス、06000
- Novartis Investigative Site
-
Nîmes、フランス、30029
- Novartis Investigative Site
-
Poissy、フランス、78303
- Novartis Investigative Site
-
Toulouse、フランス、31059
- Novartis Investigative Site
-
-
Haute Vienne
-
Limoges、Haute Vienne、フランス、87000
- Novartis Investigative Site
-
-
Val De Marne
-
Toulon、Val De Marne、フランス、83800
- Novartis Investigative Site
-
-
-
-
-
São Paulo、ブラジル、01240-020
- Novartis Investigative Site
-
-
Espírito Santo
-
Vitória、Espírito Santo、ブラジル、29055-450
- Novartis Investigative Site
-
-
Federal District
-
Brasília、Federal District、ブラジル、70200-730
- Novartis Investigative Site
-
-
Paraná
-
Curitiba、Paraná、ブラジル、81210-310
- Novartis Investigative Site
-
-
Rio Grande do Sul
-
Porto Alegre、Rio Grande do Sul、ブラジル、90430-001
- Novartis Investigative Site
-
Porto Alegre、Rio Grande do Sul、ブラジル、90560-032
- Novartis Investigative Site
-
Porto Alegre、Rio Grande do Sul、ブラジル、90620-130
- Novartis Investigative Site
-
-
Santa Catarina
-
Joinville、Santa Catarina、ブラジル、89202-165
- Novartis Investigative Site
-
-
-
-
-
Plovdiv、ブルガリア、4002
- Novartis Investigative Site
-
Sofia、ブルガリア、1309
- Novartis Investigative Site
-
Sofia、ブルガリア、1431
- Novartis Investigative Site
-
Sofia、ブルガリア、1407
- Novartis Investigative Site
-
-
-
-
-
Guaynabo、プエルトリコ、00968
- Caribbean Center for Clinical Research Inc
-
-
-
-
-
Braga、ポルトガル、4710-243
- Novartis Investigative Site
-
Coimbra、ポルトガル、3004-561
- Novartis Investigative Site
-
Leiria、ポルトガル、2410-197
- Novartis Investigative Site
-
Lisbon、ポルトガル、1649-035
- Novartis Investigative Site
-
Lisbon、ポルトガル、1169-050
- Novartis Investigative Site
-
Matosinhos Municipality、ポルトガル、4454-513
- Novartis Investigative Site
-
Santa Maria da Feira、ポルトガル、4520-211
- Novartis Investigative Site
-
-
-
-
-
Bialystok、ポーランド、15-704
- Novartis Investigative Site
-
Glogow Wielkopolski、ポーランド、36-060
- Novartis Investigative Site
-
Katowice、ポーランド、40-081
- Novartis Investigative Site
-
Katowice、ポーランド、40-571
- Novartis Investigative Site
-
Katowice、ポーランド、40-686
- Novartis Investigative Site
-
Katowice、ポーランド、40-689
- Novartis Investigative Site
-
Lublin、ポーランド、20-701
- Novartis Investigative Site
-
Wroclaw、ポーランド、51-685
- Novartis Investigative Site
-
Zabrze、ポーランド、41-800
- Novartis Investigative Site
-
-
Poznan
-
Plewiska、Poznan、ポーランド、62-064
- Novartis Investigative Site
-
-
-
-
-
Mexico City、メキシコ、14050
- Novartis Investigative Site
-
Querétaro、メキシコ、76070
- Novartis Investigative Site
-
-
Chihuahua
-
Chihuahua City、Chihuahua、メキシコ、31203
- Novartis Investigative Site
-
-
Mexico City
-
Mexico City、Mexico City、メキシコ、06700
- Novartis Investigative Site
-
-
-
-
-
Campulung Muscel、ルーマニア、115100
- Novartis Investigative Site
-
Constanța、ルーマニア、900591
- Novartis Investigative Site
-
-
ROM
-
Brasov、ROM、ルーマニア、500123
- Novartis Investigative Site
-
Constanța、ROM、ルーマニア、900123
- Novartis Investigative Site
-
-
-
-
-
Beijing、中国、100034
- Novartis Investigative Site
-
Shanghai、中国、200025
- Novartis Investigative Site
-
Shanghai、中国、200040
- Novartis Investigative Site
-
-
Hubei
-
Wuhan、Hubei、中国、430030
- Novartis Investigative Site
-
Wuhan、Hubei、中国、430060
- Novartis Investigative Site
-
-
Jiangsu
-
Nanjing、Jiangsu、中国、210029
- Novartis Investigative Site
-
-
Ningxia
-
Yinchuan、Ningxia、中国、750004
- Novartis Investigative Site
-
-
Shanxi
-
Taiyuan、Shanxi、中国、030001
- Novartis Investigative Site
-
-
Zhejiang
-
Hangzhou、Zhejiang、中国、310016
- Novartis Investigative Site
-
Hangzhou、Zhejiang、中国、310006
- Novartis Investigative Site
-
Wenzhou、Zhejiang、中国、325000
- Novartis Investigative Site
-
-
-
-
-
Pretoria、南アフリカ、0041
- Novartis Investigative Site
-
Rosebank、南アフリカ、2196
- Novartis Investigative Site
-
-
Free State
-
Bloemfontein、Free State、南アフリカ、9301
- Novartis Investigative Site
-
-
-
-
-
Fukuoka、日本、8128582
- Novartis Investigative Site
-
Niigata、日本、9518520
- Novartis Investigative Site
-
-
Aichi-ken
-
Nagoya、Aichi-ken、日本、4668560
- Novartis Investigative Site
-
-
Chiba
-
Chiba、Chiba、日本、2608677
- Novartis Investigative Site
-
Ichihara、Chiba、日本、2990111
- Novartis Investigative Site
-
-
Fukuoka
-
Fukuoka、Fukuoka、日本、8100022
- Novartis Investigative Site
-
-
Hokkaido
-
Sapporo、Hokkaido、日本、0630005
- Novartis Investigative Site
-
-
Hyōgo
-
Kobe、Hyōgo、日本、6500017
- Novartis Investigative Site
-
Nishinomiya、Hyōgo、日本、663 8501
- Novartis Investigative Site
-
-
Kanagawa
-
Isehara、Kanagawa、日本、2591193
- Novartis Investigative Site
-
Sagamihara、Kanagawa、日本、2520375
- Novartis Investigative Site
-
-
Kyoto
-
Kyoto、Kyoto、日本、6168255
- Novartis Investigative Site
-
-
Miyagi
-
Sendai、Miyagi、日本、9838512
- Novartis Investigative Site
-
-
Nara
-
Kashihara、Nara、日本、6348522
- Novartis Investigative Site
-
-
Osaka
-
Moriguchi、Osaka、日本、5708507
- Novartis Investigative Site
-
Suita、Osaka、日本、5650871
- Novartis Investigative Site
-
-
Saitama
-
Higashi-Matsuyama、Saitama、日本、3550005
- Novartis Investigative Site
-
-
Tokyo
-
Kodaira、Tokyo、日本、1878551
- Novartis Investigative Site
-
Shinjuku Ku、Tokyo、日本、1628666
- Novartis Investigative Site
-
Shinjuku Ku、Tokyo、日本、1600023
- Novartis Investigative Site
-
Shinjuku-ku、Tokyo、日本、1608582
- Novartis Investigative Site
-
tabashi City、Tokyo、日本、1738610
- Novartis Investigative Site
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- 18 to 55 years of age
- Diagnosis of RMS according to the 2017 McDonald diagnostic criteria
- At least: 1 documented relapse within the previous year. OR 2 documented relapses within the previous 2 years, OR 1 active Gadolinium (Gd)-enhancing lesion in the 12 months.
- EDSS score of 0 to 5.5 (inclusive)
- Neurologically stable within 1 month
Exclusion Criteria:
-
Diagnosis of primary progressive multiple sclerosis (PPMS)
-
Disease duration of more than 10 years in participants with EDSS score of 2 or less at screening
-
History of clinically significant CNS disease other than MS
-
Ongoing substance abuse (drug or alcohol)
-
History of malignancy of any organ system (other than complete resection of localized basal cell carcinoma of the skin or in situ cervical cancer),
-
Participants with history of confirmed Progressive Multifocal Leukoencephalopathy (PML) or Neurological symptoms consistent with PML
-
suicidal ideation or behavior
-
Evidence of clinically significant cardiovascular, neurological, psychiatric, pulmonary , renal, hepatic, endocrine, metabolic, hematological disorders or gastrointestinal disease that can interfere with interpretation of the study results or protocol adherence
-
Participants who have had a splenectomy
-
Active clinically significant systemic bacterial, viral, parasitic or fungal infections
-
Positive results for syphilis or tuberculosis testing
-
Uncontrolled disease states, such as asthma, or inflammatory bowel disease, where flares are commonly treated with oral or parenteral corticosteroids
-
Active, chronic disease of the immune system (including stable disease treated with immune therapy (e.g. Leflunomide, Methotrexate)) other than MS (e.g. rheumatoid arthritis, systemic lupus erythematosus, etc.) with the exception of well-controlled diabetes or thyroid disorder.
-
Participants with a known immunodeficiency syndrome (AIDS, hereditary immune deficiency, drug induced immune deficiency), or tested positive for HIV antibody
-
History or current treatment for hepatic disease including but not limited to acute or chronic hepatitis, cirrhosis (including all Child-Pugh classes) or hepatic failure or any chronic liver or biliary disease.
-
History of severe renal disease or creatinine level
-
Participants at risk of developing or having reactivation of hepatitis
-
Hematology parameters at screening:
- Hemoglobin: < 10 g/dl (<100g/L)
- Platelets: < 100000/mm3 (<100 x 109/L)
- Absolute lymphocyte count < 800/mm3 (<0.8 x 109/L)
- White blood cells: <3 000/mm3 (<3.0 x 109/L)
- Neutrophils: < 1 500/mm3 (<1.5 x 109/L)
- B-cell count < 50% lower limit of normal (LLN) or total IgG & total IgM < LLN (only required for participants who had a history of receiving B-cell therapies, such as rituximab, ocrelizumab or ofatumumab, prior to screening)
-
History or current diagnosis of significant ECG abnormalities
-
Resting QTcF ≥450 msec (male) or ≥460 msec (female) at pre-treatment as per central ECG reading at screening visit
-
Use of other investigational drugs
-
Requirement for anticoagulant medication or use of dual anti-platelet therapy Significant bleeding risk or coagulation disorders,
-
History of gastrointestinal bleeding
-
Major surgery within 8 weeks prior to screening
-
History of hypersensitivity to any of the study drugs or excipients
-
Pregnant or nursing (lactating) female participants, prior to randomization
-
Women of childbearing potential not using highly effective contraception
-
Sexually active males not agreeing to use condom
-
Have received any live or live-attenuated vaccines within 6 weeks of randomization or requirement to receive these vaccinations during study
-
Use of strong CYP3A4 inhibitors or use of moderate or strong CYP3A4 inducers within two weeks prior to randomization
Inclusion to Extension part:
• Participants who complete the Core Part of the study on double-blind study treatment and conduct the Accelerated Elimination Procedure (AEP)
Other inclusion and exclusion criteria may apply.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Remibrutinib - Core
Remibrutinib tablet and matching placebo of teriflunomide capsule |
tablet taken orally
他の名前:
|
|
アクティブコンパレータ:Teriflunomide - Core
Teriflunomide capsule and matching placebo remibrutinib tablet |
capsule taken orally |
|
実験的:Remibrutinib - Extension
Participants on remibrutinib in Core will continue on remibrutinib tablet |
tablet taken orally
他の名前:
|
|
実験的:Remibrutinib - Extension (on teriflunomide in Core)
Participants on teriflunomide in Core will switch to remibrutinib tablet |
tablet taken orally
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Annualized relapse rate (ARR) of confirmed relapses [Core Part]
時間枠:From Baseline, up to 30 months
|
ARR is the average number of confirmed MS relapses in a year |
From Baseline, up to 30 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Time to 3-month confirmed disability progression (3mCDP) on Expanded Disability Status Scale (EDSS) [Core Part] (pooled data)
時間枠:Baseline up to 30 months
|
Time to 3-month confirmed disability progression (3mCDP) is defined as an increase in Expanded Disability Status Scale (EDSS) which is sustained for at least 3 months |
Baseline up to 30 months
|
|
Time to 6-month confirmed disability progression (6mCDP) on EDSS [Core Part] (pooled data)
時間枠:Baseline up to 30 months
|
Time to 6-month confirmed disability progression (6mCDP) is defined as an increase in Expanded Disability Status Scale (EDSS) which is sustained for at least 6 months |
Baseline up to 30 months
|
|
Annualized rate of new or enlarging T2 lesion [Core Part]
時間枠:Baseline up to 30 months
|
Number of new/newly enlarged T2 lesions per year |
Baseline up to 30 months
|
|
Neurofilament light chain (Nfl) [Core Part]
時間枠:Baseline up to 30 months
|
Neurofilament light chain (NfL) concentration in serum |
Baseline up to 30 months
|
|
Number of Gd-enhancing T1 lesions per MRI scan [Core Part]
時間枠:Baseline up to 30 months
|
Average number of Gd-enhancing T1 lesions per scan |
Baseline up to 30 months
|
|
Percentage of participants with No Evidence of Disease Activity-3 (NEDA-3) [Core Part] (pooled data)
時間枠:Baseline up to 30 months
|
Percentage of participants with No Evidence of Disease Activity-3 (NEDA-3), as assessed by absence of confirmed MS relapses, 6mCDP and new/enlarging T2 lesions on MRI |
Baseline up to 30 months
|
|
Time to first confirmed relapse [Core Part]
時間枠:Baseline up to 30 months
|
Change in the Expanded Disability Status Scale (EDSS), an increase of at least 0.5 points on the EDSS (total) score, or an increase of at least 1 point on at least two functional scores (FSs), or an increase of at least 2 points on at least one FS, excluding changes involving bowel/bladder or cerebral FS, compared to the previous available rating. |
Baseline up to 30 months
|
|
Time to 6-month confirmed disability improvement (6mCDI) on EDSS [Core Part] (pooled data)
時間枠:Baseline up to 30 months
|
Decrease in Expanded Disability Status Scale Score (EDSS) which is sustained for at least 6 months |
Baseline up to 30 months
|
|
Time to 3-months confirmed disability progression (3mCDP) and 6-month confirmed disability progression (6mCDP) independent of relapse activity (PIRA) [Core Part] (pooled data)
時間枠:Baseline up to 30 months
|
Time to 3-month confirmed disability progression (3mCDP) and 6-month confirmed disability progression (6mCDP) is defined as an increase in Expanded Disability Status Scale (EDSS) which is sustained for at least 3 months or 6 months, respectively, without an on-study relapse before or on the day of a progression eve |
Baseline up to 30 months
|
|
Change from baseline in the Symbol Digit Modalities Test (SDMT) [Core Part] (pooled data)
時間枠:Baseline up to 30 months
|
Symbol Digit Modalities Test (SDMT), an array of symbols paired with empty spaces, measures processing in speed; participants verbally match the number for each symbol as rapidly as possible. The score is the number of correctly coded items in 90 seconds. Higher scores indicate improvement. Lower scores indicate worsening |
Baseline up to 30 months
|
|
Time to 6-month confirmed worsening by at least 20% in the Timed 25-foot walk test (T25FW) [Core Part] (pooled data)
時間枠:Baseline, up to 30 months
|
The patient walking speed to cover 25-foot distance is recorded in seconds. Longer time indicates poorer lower limb function. 20% worsening is defined as 20% increase from baseline T25FW score |
Baseline, up to 30 months
|
|
Time to 6-month confirmed worsening by at least 20% in the Timed 9-hole peg test (9HPT) (pooled data) [Core Part] (pooled data)
時間枠:Baseline up to 30 months
|
The patient's right and left arm function to peg 9 holes measured in seconds. Longer time indicates poorer upper limb function. 20% worsening is defined as 20% increase from baseline 9HPT score in at least one hand (average of two trials per hand) |
Baseline up to 30 months
|
|
Time to composite 6-month confirmed disability Progression (CDP) [Core Part] (pooled data)
時間枠:Baseline up to 30 months
|
The composite involves CDP and worsening by at least 20% in T25FW and 9HPT |
Baseline up to 30 months
|
|
Change from Baseline in T2 lesion volume [Core Part]
時間枠:Baseline up to 30 months
|
Change from baseline in total T2 lesion volume. |
Baseline up to 30 months
|
|
Change from baseline in Multiple Sclerosis Impact Scale (MSIS-29) [Core Part]
時間枠:Baseline up to 30 months
|
29-item, self-administered questionnaire that includes 2 domains, physical and psychological. Responses are captured on a 4-point scale ranging from "not at all" (1) to "extremely" (4), where higher scores reflect greater impact on day to day life |
Baseline up to 30 months
|
|
Number of participants with Adverse events and Serious adverse events(SAE) [Core Part]
時間枠:Baseline up to 30 months
|
Adverse events and SAEs including clinically significant, laboratory data, vital signs, electrocardiogram (ECG), Columbia Suicide Severity Rating |
Baseline up to 30 months
|
|
Pharmacokinetics of remibrutinib [Core Part]
時間枠:Month 1, Month 6
|
Blood concentrations of remibrutinib |
Month 1, Month 6
|
|
Number of participants with Adverse events and Serious adverse events (SAE) [Extension Part]
時間枠:Day 1 Extension up to 5 years
|
Adverse events and SAEs including clinically significant, laboratory data, vital signs, electrocardiogram (ECG), Columbia Suicide Severity Rating |
Day 1 Extension up to 5 years
|
|
Annualized relapse rate (ARR) of confirmed relapses [Extension Part]
時間枠:Day 1 Extension up to 5 years
|
ARR is the average number of confirmed MS relapses in a year |
Day 1 Extension up to 5 years
|
|
Annualized rate of new or enlarging T2 lesion [Extension Part]
時間枠:Day 1 Extension up to 5 years
|
Number of new/newly enlarged T2 lesions per year |
Day 1 Extension up to 5 years
|
|
Time to 6-month confirmed disability progression (6mCDP) on EDSS [Extension Part]
時間枠:Day 1 Extension up to 5 years
|
Time to 6-month confirmed disability progression (6mCDP) is defined as an increase in Expanded Disability Status Scale (EDSS) which is sustained for at least 6 months |
Day 1 Extension up to 5 years
|
|
Change from baseline in the Symbol Digit Modalities Test (SDMT) [Extension Part]
時間枠:Day 1 Extension up to 5 years
|
Symbol Digit Modalities Test (SDMT), an array of symbols paired with empty spaces, measures processing in speed; participants verbally match the number for each symbol as rapidly as possible. The score is the number of correctly coded items in 90 seconds. Higher scores indicate improvement. Lower scores indicate worsening |
Day 1 Extension up to 5 years
|
|
Neurofilament light chain (NfL) [Extension Part]
時間枠:Day 1 Extension up to 5 years
|
Neurofilament light chain (NfL) concentration in serum |
Day 1 Extension up to 5 years
|
|
Change from baseline in Multiple Sclerosis Impact Scale (MSIS-29) [Extension Part]
時間枠:Day 1 Extension up to 5 years
|
29-item, self-administered questionnaire that includes 2 domains, physical and psychological. Responses are captured on a 4-point scale ranging from "not at all" (1) to "extremely" (4), where higher scores reflect greater impact on day to day life |
Day 1 Extension up to 5 years
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Novartis Pharmaceuticals、Novartis Pharmaceuticals
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- CLOU064C12302
- 2023-509372-41-00 (レジストリ識別子:EU CTIS)
- 2023 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。